AZN, Daiichi's Enhertu gets FDA nod for two new breast cancer settings
- Posted on May 18, 2026
- By Bing News
- 0 Views
- 1 min read
AZN, Daiichi's Enhertu gets FDA nod for two new breast cancer settings
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for two new breast cancer indications. The drug is now approved for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. The approvals were based on data from the phase III DESTINY-Breast11 and DESTINY-Breast05 studies, respectively. In the neoadjuvant...
